Talk Bio

Through Flux and Fluidity, FDA Keeps Coming Back to Rare Disease: 2026 Policy Shifts and Approvals in Rare Disease Space

Busy FDA gives rare disease sector complementary pathways, unanswered questions – 2026 snapshot

Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval

FDA Unveils 'Plausible Mechanism Pathway' to Accelerate Personalized Therapies, Inspired by Baby KJ